drugset / Trial / NCT06757335
A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or metastatic breast cancer.
Timeline
- Start
- 2025-01-07
- Primary completion
- 2026-01-31
- Completion
- 2026-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HP568 | Unknown | — | Oral |
| Subject | Palbociclib | Small molecule | — | — |